FierceBiotech10h
Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
ALS sidelined this Israeli TV journalist. AI is helping him make a comeback.
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
FierceBiotech2d
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
How AI Gave TV Reporter His Voice Back
The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS ...
ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Philanthropist commits $20 million to university for ALS research
Heartland Real Estate Partners founder and chairman David Husman committed $20 million to Nova Southeastern University to ...
Hosted on MSN12h
Stephen Hawking's chilling AI warnings resonate today
Stephen Hawking would have turned 83 years old. Unfortunately, the world-renowned physicist passed away in 2018. Before his ...
An Israeli TV reporter lost his ability to speak clearly. AI is helping him get back on air
When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.
Science Daily1d
Potential new therapeutic targets for Huntington's disease
A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...
PharmiWeb14h
Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...